KR20210034055A - Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 - Google Patents

Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 Download PDF

Info

Publication number
KR20210034055A
KR20210034055A KR1020217005032A KR20217005032A KR20210034055A KR 20210034055 A KR20210034055 A KR 20210034055A KR 1020217005032 A KR1020217005032 A KR 1020217005032A KR 20217005032 A KR20217005032 A KR 20217005032A KR 20210034055 A KR20210034055 A KR 20210034055A
Authority
KR
South Korea
Prior art keywords
ser
leu
thr
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217005032A
Other languages
English (en)
Korean (ko)
Inventor
가오루 우치마루
마코토 야마기시
이즈미 이시자키
요시히사 야마노
Original Assignee
고쿠리츠다이가쿠호우진 도쿄다이가쿠
가코우호우진 세이마리안나 이카다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호우진 도쿄다이가쿠, 가코우호우진 세이마리안나 이카다이가쿠 filed Critical 고쿠리츠다이가쿠호우진 도쿄다이가쿠
Publication of KR20210034055A publication Critical patent/KR20210034055A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217005032A 2018-07-19 2019-07-19 Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 Ceased KR20210034055A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
JPJP-P-2018-135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Publications (1)

Publication Number Publication Date
KR20210034055A true KR20210034055A (ko) 2021-03-29

Family

ID=69163691

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005032A Ceased KR20210034055A (ko) 2018-07-19 2019-07-19 Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법

Country Status (16)

Country Link
US (1) US20210269535A1 (cg-RX-API-DMAC7.html)
EP (2) EP4656657A3 (cg-RX-API-DMAC7.html)
JP (4) JP7150286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034055A (cg-RX-API-DMAC7.html)
CN (4) CN116850291A (cg-RX-API-DMAC7.html)
AU (1) AU2019306721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112511A1 (cg-RX-API-DMAC7.html)
IL (1) IL280257A (cg-RX-API-DMAC7.html)
MX (1) MX2021000732A (cg-RX-API-DMAC7.html)
PE (2) PE20260298A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100561QA (cg-RX-API-DMAC7.html)
TW (2) TWI825131B (cg-RX-API-DMAC7.html)
WO (1) WO2020017629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101113B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070749A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010100578A (ja) 2008-10-24 2010-05-06 St Marianna Univ School Of Medicine Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を予測する方法
KR20110071059A (ko) 2008-09-02 2011-06-28 도레이 토넨 기노우마쿠 고도카이샤 미세다공성 고분자막, 이 미세다공성 고분자막의 제조방법 및 전지 세퍼레이터 필름으로서의 이 미세다공성 고분자막의 사용
JP2014138599A (ja) 2008-02-29 2014-07-31 Abbott Gmbh & Co Kg Rgmaタンパク質に対するモノクローナル抗体及びその使用
JP2017526930A (ja) 2014-09-10 2017-09-14 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー RGMa断片ベース診断アッセイ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
CA2824515C (en) * 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症患者の治療方法および治療剤
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW202523689A (zh) * 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014138599A (ja) 2008-02-29 2014-07-31 Abbott Gmbh & Co Kg Rgmaタンパク質に対するモノクローナル抗体及びその使用
JP2016175897A (ja) 2008-02-29 2016-10-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Rgm aタンパク質に対するモノクローナル抗体及びその使用
KR20110071059A (ko) 2008-09-02 2011-06-28 도레이 토넨 기노우마쿠 고도카이샤 미세다공성 고분자막, 이 미세다공성 고분자막의 제조방법 및 전지 세퍼레이터 필름으로서의 이 미세다공성 고분자막의 사용
JP2010100578A (ja) 2008-10-24 2010-05-06 St Marianna Univ School Of Medicine Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を予測する方法
JP2017526930A (ja) 2014-09-10 2017-09-14 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー RGMa断片ベース診断アッセイ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N Engl J Med, 2018, 378, 529-538.

Also Published As

Publication number Publication date
TW202408577A (zh) 2024-03-01
JP2024095754A (ja) 2024-07-10
CN112566664B (zh) 2023-08-25
CN112566664A (zh) 2021-03-26
CN116942831A (zh) 2023-10-27
PE20211376A1 (es) 2021-07-27
JPWO2020017629A1 (ja) 2021-08-02
PE20260298A1 (es) 2026-02-10
ZA202101113B (en) 2022-07-27
CN116850291A (zh) 2023-10-10
JP2022180487A (ja) 2022-12-06
JP2025134820A (ja) 2025-09-17
CA3112511A1 (en) 2020-01-23
EP3824907B1 (en) 2025-09-17
SG11202100561QA (en) 2021-02-25
IL280257A (en) 2021-03-25
WO2020017629A1 (ja) 2020-01-23
EP3824907A1 (en) 2021-05-26
TWI825131B (zh) 2023-12-11
EP3824907A4 (en) 2022-05-04
EP4656657A3 (en) 2026-02-25
JP7475011B2 (ja) 2024-04-26
AU2019306721A1 (en) 2021-03-11
PH12021550134A1 (en) 2021-09-27
EP4656657A2 (en) 2025-12-03
MX2021000732A (es) 2021-04-28
CN116785439A (zh) 2023-09-22
JP7703174B2 (ja) 2025-07-07
BR112021000949A2 (pt) 2021-04-27
AU2019306721B2 (en) 2024-09-05
JP7150286B2 (ja) 2022-10-11
TW202019482A (zh) 2020-06-01
US20210269535A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR102223464B1 (ko) T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
JP5552630B2 (ja) Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法
JP2025134820A (ja) Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
CA2824313A1 (en) Tlr3 binding agents
RU2833547C2 (ru) Терапевтический или профилактический агент для htlv-1-ассоциированной миелопатии (ham) и способ лечения ham
KR20230154239A (ko) 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체
CN114616245A (zh) 一种抗cd38的抗体及其用途
HK40054121A (en) Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method
US20250154238A1 (en) Methods and compositions for treating and preventing fibrosis
JP2025118705A (ja) 末梢神経再生を促進するためのcxcl13結合分子の使用
WO2021085295A1 (ja) 免疫応答抑制剤
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000